ABCB5 and acute kidney injury: Finally, clinical-grade ABCB5+ MSCs were administered in a therapeutic AKI model, injecting a single dose of ABCB5+ MSCs either intravenously (i.v.)or intraperitoneally (i.p.)on day 3 after cisplatin treatment.